Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine prophylaxis for cognitive impairment during electroconvulsive therapy in major depressive disorder
2014-004393-41Phase 3Completed
- Sponsor
- Erasmus Hospital
- Start
- Apr 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Galantamine prophylaxis with Placebo control (2 arms). Started Apr 2015; status: completed.
02
Drugs
galantamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2014-004393-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004393-41.